Recombinant Zebrafish AGXTA

• Cat.No.: AGXTA-480Z
• Product Overview: Recombinant Zebrafish AGXTA full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: agxta alanine-glyoxylate aminotransferase a [ Danio rerio (zebrafish) ]
• Official Symbol: AGXTA
• Gene ID: 436603
• mRNA Refseq: NM_001002331
• Protein Refseq: NP_001002331
• UniProt ID: Q6DG86

Reviews

01/18/2022

The customer support team was extremely helpful and responsive, providing detailed information about the products.

02/02/2021

Impeccable quality!

11/22/2020

My lab is never running out of this recombination protein – it's become an essential part of our experiments.

03/04/2020

They offer excellent value for the price.

12/07/2018

What a difference this protein has made in my research – truly outstanding.

Q&As

How does AGXTA activity vary across different age groups and populations?

AGXTA activity levels can vary depending on age, gender, and genetic background, contributing to differences in oxalate metabolism and the risk of developing kidney stones.

What is the role of AGXTA in hepatic peroxisomal function and metabolism?

AGXTA is a peroxisomal enzyme that participates in the glyoxylate metabolic pathway, which is vital for peroxisomal function and the maintenance of peroxisomal homeostasis.

How do AGXTA mutations lead to the pathogenesis of primary hyperoxaluria type 1?

AGXTA mutations result in the impaired function of the enzyme, leading to the accumulation of glyoxylate, which is then converted into oxalate. High oxalate levels can cause kidney stones and kidney damage.

How can structural biology techniques, such as X-ray crystallography and cryo-electron microscopy, aid in understanding AGXTA's catalytic mechanism?

Structural biology techniques can provide atomic-level details of AGXTA's active site and substrate-binding interactions, elucidating the enzymatic process of glyoxylate metabolism.

What is the relevance of AGXTA in the context of primary hyperoxaluria type 1 (PH1)?

Mutations in the AGXT gene can lead to the deficiency or malfunction of AGXTA, causing PH1, a rare genetic disorder characterized by excessive oxalate accumulation and kidney stone formation.

How is AGXTA expression regulated, and what tissues or organs express this enzyme?

AGXTA expression is regulated by various factors, including the peroxisome proliferator-activated receptor alpha (PPARα) and hepatocyte nuclear factor 4 alpha (HNF4α). It is predominantly expressed in the liver, but also found in the kidney and other tissues.

Does AGXTA have any interaction partners or participate in metabolic pathways beyond glyoxylate metabolism?

AGXTA may have interactions with other enzymes or proteins involved in peroxisomal metabolism and could play a role in various cellular processes beyond glyoxylate metabolism.

Can dietary factors modulate AGXTA activity and oxalate metabolism?

Yes, certain dietary components, such as vitamin B6, calcium, and oxalate-rich foods, can influence AGXTA activity and oxalate production, potentially impacting the development of kidney stones.

How can advances in pharmacogenomics contribute to personalized treatment approaches for primary hyperoxaluria type 1?

Pharmacogenomic studies can help identify genetic factors that influence individual responses to treatments, facilitating the development of personalized therapeutic strategies for PH1 patients.

Can AGXTA dysfunction contribute to other medical conditions besides primary hyperoxaluria type 1?

Yes, AGXTA mutations or dysregulation have been associated with other conditions, such as focal segmental glomerulosclerosis (FSGS) and idiopathic calcium oxalate urolithiasis.